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Introduction
============

The fundamental scientific problem of life sciences, especially modern molecular biology and fundamental medicine, is the development of approaches to the directed action on the genetic material of cells. Fragments of nucleic acids (oligonucleotides and their derivatives and analogs) can be used for this purpose because they are known to site specifically interact with certain regions of nucleic acid (NA) targets. The development of antisense technology for the creation of drugs that can gene specifically affect the genes responsible for infectious, hereditary, cancer, and cardiovascular diseases is an important task of modern medicine and pharmacology. The selective recognition of molecular targets by NA-based therapeutics may minimize negative side effects compared to conventional pharmaceuticals that typically have less specificity.

Influenza A viruses (IAVs) are prominent in infectious diseases of humans and animals and periodically cause epidemics and epizootics. At present, the development of new antiviral drugs based on native or chemically modified nucleic acids is under scrutiny. Researchers all over the world explore the therapeutic potential of NA-based drugs to fight against the genetically variable viruses including IAV.

Many attempts to produce effective antiviral drugs against IAV have not yet been successful because of the low ability of NA-based drugs to penetrate into cells. In the last few years, there were a large number of publications describing different delivery systems of nucleic acid fragments into cells \[[@R1]--[@R3]\], including the use of inorganic nanoparticles \[[@R4]\].

Another important problem of using NA-based drugs is to select a proper target in the IAV genome. The choice of the most efficient antiviral NA-based drugs to affect IAV replication may contribute to the creation of therapeutic preparations, the activity of which would be less dependent on mutations. The IAV genome contains eight single-stranded RNA segments of negative polarity and belongs to the Ortomyxoviridae family. All eight segments are important for the viral replication. After infection of cells, the viral (−)RNA segments are transcribed into (+)mRNA and replicated into (+)cRNA \[[@R5]\]. The IAV genome is known for its high variability. The most variable genes are segments 4 and 6, encoding hemagglutinin and neuraminidase, respectively. Segments 1, 2, 3, 5, and 7, encoding RNA-dependent RNA polymerases (PB2, PB1, and PA), nucleoprotein (NP), and matrix protein M1, respectively, comprise the largest number of conserved sequences \[[@R6]\]. The NP plays a key role in the migration of the viral RNAs to cell nuclei of infected cells and in the following replication and assembly of the virus \[[@R7]\]. Therefore, many researchers believe that segment 5, which encodes this protein, is an ideal target to block the virus reproduction by antiviral compounds \[[@R8]--[@R10]\].

Different regions of segment 5 have been studied for their sensitivity to the action of NA-based drugs of various nature \[[@R8]--[@R16]\]. However, there is still no unified concept for the most vulnerable regions of this segment. In this work, we attempt to find some relationships in this aspect for IAV segment 5.

To deliver antisense oligonucleotides into cells, we previously proposed the TiO~2~·PL--DNA system \[[@R17]\], where oligonucleotides were noncovalently immobilized on TiO~2~ nanoparticles through the polylysine (PL) linker. It was shown that TiO~2~·PL--DNA nanocomposites can penetrate into cells without any additional treatment (i.e., transfection agents or physical impact). It was demonstrated that these nanocomposites exhibited a low toxicity and very high activity against IAV in the cell culture \[[@R18]--[@R19]\]. Only one site in the IAV 5 segment was used in our previous works.

In this work, we examined the antiviral activity of DNA fragments in the proposed TiO~2~·PL--DNA nanocomposites, targeted to conservative regions of (−)RNA and (+)RNA of different IAV subtypes (H1N1, H5N1, and H3N2).

Results and Discussion
======================

The choice of the most suitable regions in nucleic acids for oligonucleotide-based agents is of great importance. In order to inhibit the different subtypes of viruses, these regions should have conservative nucleotide sequences and be accessible for the interaction with complementary oligonucleotides. As many other researchers have \[[@R8]--[@R16]\], we have chosen segment 5 (encoding nucleoprotein (NP)) of IAV genome as a target to affect the virus replication. To find the most conservative regions of segment 5, we analyzed nucleotide sequences of various subtypes of IAV available in the NCBI Influenza Virus Resource database (http://www.ncbi.nlm.nih.gov). We have chosen the four most conservative regions, i.e. the noncoding region located on the 3'-end of (+)cRNA after the stop codon (1544--1564), the nearby coding region close to the stop codon (1498--1516), the region including the AUG codon (34--54), and the 5'-noncoding region (2--22), where the nucleotide numbering is given for (+)cRNA. The short 5'- and 3'-terminal nontranslated regions (NTRs) are of considerable interest because all eight RNA segments of various IAV subtypes are known to contain conserved sequences of 13 or 12 nucleotides at their 5' and 3' ends (^5'^AGUAGAAACAAGG^3'^and ^5'^CCUGCUUUUGCU^3'^, respectively) \[[@R20]--[@R21]\].

The region including the AUG codon in (+)RNA \[[@R11],[@R14]\] and the 3'-terminal region of (−)RNA \[[@R10]--[@R11]\] were the most chosen regions of IAV segment 5 to be affected by oligonucleotides and their analogs. The coding region close to the stop codon was often used as the target for the action of siRNA \[[@R9],[@R12],[@R15]--[@R16]\]. The other regions of the NP gene were also studied as targets \[[@R8],[@R11]--[@R12] [@R21]\]. It can be concluded from these literature data that the most susceptible regions for the action of NA-based drugs are the first two regions mentioned above. Nevertheless, a comprehensive study was not performed concerning the susceptibility of different regions of the IAV segment 5 to the action of NA-based compounds, which was attempted in the presented work.

As mentioned above, after infection of cells viral (−)RNA are transcribed into (+)mRNA and replicated into complementary (+)cRNA \[[@R5]\]. To affect the viral genome, we used oligodeoxynucleotides directed to four selected conserved regions of the NP gene, which were complementary to both (−)RNA and (+)RNA ([Table 1](#T1){ref-type="table"}). The localization of these DNA fragments on viral RNA is depicted in [Fig. 1](#F1){ref-type="fig"}. The nucleotide sequences were chosen so that they had the terminal G/C nucleotides to provide more stable complexes with the target and did not form the hairpin and self-complementary structures. All oligonucleotides were 19--21-mers. In addition to these oligonucleotides, a random sequence (DNA-r) was used as a control.

###### 

Oligonucleotides aimed at different regions of influenza A virus segment 5.

  --------------------------- -------- ----------------------------------- --------------------------
  Sequence, 5'→3'             Name     Targeted at                         Position in segment 5^a^
                                                                           
  GATTATCTACCCTGCTTTTGCp      DNA~1~   5'-noncoding region of (+)RNA       2--22
  GCAAAAGCAGGGTAGATAATCp^b^   DNA~5~   corresponding 3'-region of (−)RNA   
  GAGACGCCATGATGTTGATGTCp     DNA~2~   AUG region of (+)RNA                34--54
  GACATCAACATCATGGCGTCTCp     DNA~6~   corresponding region of (−)RNA      
  CTCCGAAGAAATAAGATCCp        DNA~3~   3'-coding region of (+)RNA          1498--1516
  GGATCTTATTTCTTCGGAGp        DNA~7~   corresponding 5'-region of (−)RNA   
  GTAGAAACAAGGGTATTTTTCp      DNA~4~   3'-noncoding region of (+)RNA       1544--1564
  GAAAAATACCCTTGTTTCTACp      DNA~8~   corresponding 5'-region of (−)RNA   
  GATCAACTCCATATGCCATGTp      DNA~r~   random                              --
  --------------------------- -------- ----------------------------------- --------------------------

^a^Numbering of nucleotides are given for (+)RNA; ^b^Nanocomposite TiO~2~·PL--DNA containing this DNA fragment was used in previous works \[[@R18]--[@R19]\].

![Scheme of localization of the used DNA fragments on influenza A virus segment 5. AUG is the initiation codon for translation of the nucleoprotein gene.](Beilstein_J_Nanotechnol-07-1166-g002){#F1}

The synthetic DNA fragments were conjugated with polylysine (PL), and the resultant PL--DNA conjugates were noncovalently immobilized on TiO~2~ nanoparticles (≈5 nm in diameter) in the anatase form \[[@R17]\] due to the affinity of polylysine to the TiO~2~ surface. This affinity can be explained in all likelihood by the electrostatic interaction between the positively charged amino groups of PL and the negatively charged TiO~2~ surface at neutral pH \[[@R22]\]. Since the PL--DNA conjugate contains a 100-fold excess of the amino groups over an oligonucleotide \[[@R17]\], the majority of the amino groups are free to interact with the negatively charged surface of the TiO~2~ nanoparticles.

The resultant TiO~2~·PL--DNA nanocomposite was used to inhibit the reproduction of IAV in cell culture. TiO~2~ nanoparticles (of ≈5 nm in diameter) are known to penetrate through cell membrane \[[@R23]\]. It was clearly demonstrated in our previous work \[[@R17]--[@R18]\] that they are good vehicles to transport DNA fragments into cells. There are literature data that show that nanoparticles protect oligonucleotides against nucleases \[[@R24]\]. We think that in our case TiO~2~ nanoparticles may also play a protective role. In addition, the PL linker attached to the 3'-end of the DNA fragment in PL--DNA also protects oligonucleotides from cellular nucleases. Thus, native DNA fragments with phosphodiester internucleotide bonds can be used without any additional modification.

We investigated the antiviral action of eight nanocomposites of this type bearing DNA fragments complementary to eight conservative regions of RNA segment 5 of negative and positive polarity ([Fig. 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}) of different IAV subtypes.

The inhibiting effect of the chosen DNA fragments on the virus reproduction was examined in MDCK cells infected with one of three different subtypes of influenza A virus (H1N1, H3N2, and H5N1).

The antiviral activity of the nanocomposites was studied in the postinfection assays, that is, the cells were initially infected with the virus and then incubated with nanocomposites. The experiments were carried out at a multiplicity of infection (MOI) of 0.1 TCID~50~/cell and at 5 µg/mL concentration of the nanocomposites, which corresponded to a 0.1 µM concentration for the DNA fragment. This nanocomposite concentration was much lower than TC~50~/mL (1800 µg/mL \[[@R18]\]). The results are presented in terms of the TCID~50~/mL values in [Table 2](#T2){ref-type="table"}. [Table 2](#T2){ref-type="table"} also shows the extent of the IAV inhibition (*n*-fold) with the studied nanocomposites in comparison with the control without any samples. In addition, the results are demonstrated in [Fig. 2](#F2){ref-type="fig"} in terms of logTCID~50~/mL.

###### 

Antiviral activity of the studied TiO~2~·PL--DNA nanocomposites. Virus titers and inhibition of virus reproduction (*n*-fold) in MDCK cells infected with different IAV subtypes after treating with nanocomposites bearing DNA fragments complementary to four conservative regions of (−)RNA and (+)RNA of segment 5.

  ------------- ------------------- --------------- ------------- ------------- ------------- ----------- ------------- -----------
                Sample              Targeted at     H1N1          H3N2          H5N1                                    
                                                    Virus titer   ≈*n*-fold     Virus titer   ≈*n*-fold   Virus titer   ≈*n*-fold
  TCID~50~/mL                       TCID~50~/mL                   TCID~50~/mL                                           
                                                                                                                        
  1             TiO~2~·PL--DNA~1~   (+)RNA          1413          80            19953         38          31623         35
  2             TiO~2~·PL--DNA~2~   398             300           3162          240           19953       60            
  3             TiO~2~·PL--DNA~3~                   28184         4             891251        1           316228        4
  4             TiO~2~·PL--DNA~4~                   25119         4             794328        1           398107        3
  5             TiO~2~·PL--DNA~5~   (−)RNA          112           1000          86            8900        251           4500
  6             TiO~2~·PL--DNA~6~   251             460           501           1500          2239        500           
  7             TiO~2~·PL--DNA~7~                   794           150           1080          700         2512          450
  8             TiO~2~·PL--DNA~8~   19953           6             25119         30            112202      10            
  9             TiO~2~·PL--NA~r~    controls        15849         7             50119         15          199526        6
  10            TiO~2~              --              --            702583        1             1037884     1             
  11            TiO~2~·PL           --              --            532753        1.4           781882      1.5           
  12            w/o sample          virus control   116591                      762957                    1141563       
  ------------- ------------------- --------------- ------------- ------------- ------------- ----------- ------------- -----------

![IAV titers in MDCK cells infected with H1N1, H3N2, and H5N1 IAV subtypes and treated with TiO~2~·PL--DNA nanocomposites containing DNA~1~--DNA~8~ fragments (columns 1--8, respectively). The location of these fragments on IAV strands can be seen in [Fig. 1](#F1){ref-type="fig"}. The nanoparticle concentration was 5 μg/mL and the DNA fragment concentration was 0.1 μM (20 nmol/mg). The values are mean values from three experiments. The results are given for the studied samples targeted to (a) (+)RNA and (b) (−)RNA.](Beilstein_J_Nanotechnol-07-1166-g003){#F2}

First of all, it should be noted that the studied nanocomposites containing the DNA fragments targeted to (−)RNA of IAV segment 5 were more efficient against the virus as compared to those targeted to (+)RNA (compare rows 1--4 and 5--8 in [Table 2](#T2){ref-type="table"} and columns of the same color in [Fig. 2](#F2){ref-type="fig"} and [Fig. 2](#F2){ref-type="fig"}). Three of the nanocomposites inhibited the virus replication by factors higher than 100 (rows 5--7 in [Table 2](#T2){ref-type="table"} and columns 5--7 in [Fig. 2](#F2){ref-type="fig"}) for all studied strains. The most pronounced difference (by 1--3 orders of magnitude) between the nanocomposites aimed at the (+)RNA and (−)RNA was detected for the DNA~1~/DNA~5~ pair ([Table 2](#T2){ref-type="table"}, row 1 vs row 5; [Fig. 2](#F2){ref-type="fig"},b, columns 1 vs columns 5) and DNA~3~/DNA~7~ pairs **(** [Table 2](#T2){ref-type="table"}, row 3 vs row 7; [Fig. 2](#F2){ref-type="fig"}, columns 3 vs columns 7) when one of the oligonucleotide of the pair showed either very high (DNA~5~) or very low (DNA~3~) activity. There is a small difference (if at all) between the counterparts when they both exhibit either the low or high activity (the DNA~4~/DNA~8~ and DNA~2~/DNA~6~ pairs, respectively).

It can be seen that the nanocomposites bearing the DNA fragments targeted to (−)RNA became more potent as they move along the (−)strand from the 5' to the 3' end (rows 8 to 5) ([Fig. 2](#F2){ref-type="fig"}, columns DNA~8~ to DNA~5~ **)**. Thus, the DNA~5~ fragment, which inhibited the virus reproduction by up to 3--4 orders of magnitude (row 5), appeared to be the most active while the DNA~8~ fragment targeted to the opposite 5'-end of (−)RNA (row 8) showed low activity.

Only one of the studied nanocomposites containing the DNA fragment complementary to (+)RNA was quite active (row 2, columns 2), which was TiO~2~·PL--DNA~2~ bearing the DNA fragment targeted to the AUG region of (+)RNA. And yet, the antiviral activity of this fragment was lower than that of the corresponding DNA fragment targeted to (−)RNA (compare rows 2 and 6 in [Table 2](#T2){ref-type="table"}, and columns 2 and 6 in [Fig. 2](#F2){ref-type="fig"}). The TiO~2~·PL--DNA~2~ nanocomposites are superior to the TiO~2~·PL--DNA~1~ nanocomposite **(**compare row 1 and 2, and columns 1 and 2) with regards to the antiviral effect, and the difference between DNA~4~ and DNA~5~ fragments is low (rows 4 and 5, columns 4 and 5). Thus, in the case of the (+)RNA strand, there is no regular increase or decrease in the activity of the DNA fragments as they move along this strand.

It is not surprising that for all studied subtypes, the difference between the nanocomposites bearing the site-directed DNA fragments and those containing the random sequence was significant. The maximal difference of 2--3 orders of magnitude was observed for the most efficient nanocomposite (TiO~2~·PL--DNA~5~, [Table 2](#T2){ref-type="table"}).

Summarizing the results, we can say that four of eight examined sites of (+)RNA and (−)RNA of IAV segment 5 were the most vulnerable to the action of the DNA fragments in the proposed nanocomposites. Specifically, the AUG region of (+)RNA and the corresponding region of (−)RNA, the region in (−)RNA complementary to the coding region in (+)RNA, and especially the 3'-end of (−)RNA (rows 2, 6, 7, and 5, respectively, in [Table 2](#T2){ref-type="table"}). In contrast, the 3'-noncoding and nearby coding regions of (+)RNA, as well as corresponding to the former the 5'-end of (−)RNA, were the least susceptible (if at all) to the antiviral action of the proposed nanocomposites (rows 4, 3, 8 and columns 4, 3, 8, respectively). Their activities were comparable with the action of the DNA fragment with a random sequence ([Table 2](#T2){ref-type="table"}, row 10).

The fact that the initial viral (−)RNA of IAV segment 5 is more vulnerable to the action of DNA fragments than the (+)strand may indicate that the negative strand is attacked immediately after its release from the complex with the viral proteins (nucleoprotein and polymerases) before transcription into (+)mRNA and replication into complementary (+)cRNA.

The most efficient DNA~5~ oligonucleotide directed to the 3'-noncoding region of (−)vRNA contains the conserved sequence of 12 nucleotides common for all eight RNA segments of various IAV strains. Most likely, the observed strong effect of this fragment is partially explained by its simultaneous action to the other segments of the viral genome.

It should be noted that the use of the proposed TiO~2~·PL--DNA nanocomposites leads to the more efficient inhibition of the IAV replication as compared to the data of other researchers who used NA-based agents against IAV segment 5 \[[@R8]--[@R16]\].

Transfection of the IAV-infected MDCK cells with phosphorothioate oligonucleotide (4 µM) targeted to the internal coding regions of the (+)strand of the NP gene (NP-267, NP-628, and NP-749) in the presence of lipofectamine led to a slight reduction of the virus titer by 0.93--1.23 log \[[@R8]\]. The DOTAP-mediated transfection of the clone 76 cells with phosphorothioate oligonucleotides directed to the AUG region of (+)RNA of different segments, including the NP segment, demonstrated a little more than 50% inhibition of IAV at 0.3 µM concentration \[[@R14]\]. Duan et al. \[[@R25]\] used a 13-mer phosphorothioate oligonucleotide directed to the 5'-terminal region of (−)RNA of segment 5 (the fragment of our DNA~8~). They showed that this DNA fragment was efficient against various strains of IAV. The best IC~50~ and SI~50~ values were 2.22 µM and 394, respectively. Unfortunately, the authors did not indicate the level of the virus inhibition.

Morpholino oligonucleotides with the same sequences as our DNA~5~, DNA~1~, DNA~8~, and DNA~4~ were examined against the NP segment \[[@R10]\]. To ensure the delivery into cells, morpholino oligonucleotides were conjugated to an arginine-rich peptide. The efficiency of the used oligomers were in the following order: DNA~1~ \<\< DNA~8~ \< DNA~4~ ≤ DNA~5~ (reduction by 50% or 2-fold, 75% or 4-fold, 85% or 7-fold, and 98% or 50-fold, respectively, at 5 µM concentration). This order differed from our case (DNA~4~ \<\< DNA~1~ ≈ DNA~8~ ≤ DNA~5~) but the most efficient DNA fragment was the same, although its efficiency in the virus inhibition was still significantly lower even at higher concentration than in our case (3--4 orders of magnitude at 0.1 µM concentration). Morpholino oligonucleotides targeted at the NP gene with the sequence as our DNA~5~ and DNA~2~ fragments showed high inhibitory activity in cells infected by influenza A H7N7 virus (the viral replication was reduced by 3 and 6 log TCID~50~/mL, respectively, at a MOI of 0.001 and 5 µM concentration of oligomers) \[[@R11]\]. The DNA~4~ morpholino oligonucleotide displayed very low activity in these experiments. It was shown \[[@R21]\] that a 12-mer oligonucleotide directed to the 3'-end of (−)RNA of all IAV segments and delivered into cells with lipofectamine inhibited the IAV replication by 60% (2.5-fold) at a MOI of 0.1 and 5 nM concentration.

The above literature data confirm the idea about the usefulness of NA-based agents as antiviral drugs. Our results along with the literature data show that the 3'-nontranslated and AUG-containing conserved regions are most vulnerable for the antiviral action of NA-based compounds.

It should be emphasized that our experiments were carried out at a relatively high infection of cells (0.1 MOI) and at a low concentration of unmodified DNA fragments (0.1 µM) in the nanocomposites. The most active DNA~5~ fragment inhibited the reproduction of virus of the H1N1, H5N1, and H3N2 strains by factors of ≈1000, ≈3500, and ≈9000, respectively ([Table 2](#T2){ref-type="table"}), which was much higher than the effect of DNA fragments described in literature. The working concentration of the nanocomposites (5 µg/mL) was much lower than the TC~50~/mL value (1800 µg/mL) \[[@R18]\]).

Conclusion
==========

For the effective delivery of oligonucleotides into cells, we used TiO~2~·PL--DNA nanocomposites capable of penetrating without transfection reagents or physical impact. DNA fragments in the TiO~2~·PL--DNA nanocomposites were targeted to conservative regions of (−)RNA and (+)RNA of influenza A virus of the H1N1, H5N1, and H3N2 subtypes.

We found some patterns of localization of the most vulnerable regions in IAV segment 5 for the action of DNA-based drugs, where these patterns were the same for all tested subtypes. The (−)RNA of segment 5 appeared to be a more vulnerable strand of IAV as compared to the corresponding (+)RNA strand. The most sensitive sites in the IAV segment 5 to the action of the proposed agents were found to be the AUG-containing site in (+) RNA, the corresponding region in (−)RNA, and especially the 3'-noncoding region of (−)RNA. The most efficient TiO~2~·PL--DNA~5~ nanocomposite was highly active against all three strains (H1N1, H5N1, and H3N2), with the H3N2 strain being the most susceptible to the antiviral effect of the proposed nanocomposites. The results of this work may be taken into account when choosing suitable targets in the IAV genome for the action of nucleic acid-based drugs.

It should be noted that the effect of the most efficient nanocomposites on the viral reproduction (inhibition of the IAV replication by 3--4 orders of magnitude) was higher than that of other NA-based compounds described in literature (especially if the conditions used are taken into account, i.e., concentration of compounds and multiplicity of infection). It is important to emphasize that we used the most affordable, inexpensive, unprotected phosphodiester oligodeoxynucleotides.

Owing to their remarkable antiviral activity, the proposed TiO~2~·PL--DNA nanocomposites offer great potential to serve as platforms for drug development against a broad array of diseases involving nucleic acids that spans from infectious diseases to hereditary disorders.

Experimental
============

Materials and methods
---------------------

All chemicals were obtained from commercial suppliers: RPMI-1640 medium; antibiotics (BioloT, Russia); trypsin, L-glutamine; PBS buffer (Sigma, USA); and fetal calf serum (Gibco, USA). TiO~2~ nanoparticles were synthesized in the crystal form (anatase) as described in \[[@R17]\]. Сhicken erythrocytes, MDCK cells, and influenza A virus strains Aichi/2/68 (H3N2), A/chicken/Kurgan/05/2005(H5N1), and А/Salekhard/01/2009 (H1N1) were from FBRI Vector, Russia. Trypsin (1 mg/mL) and penicillin-streptomycin (100 U/mL) (Sigma-Aldrich, USA) were stored at −80 °C. The IAV strains were grown in the allantoic cavity of 10-day-old embryonated chicken eggs at 37 °C. Allantoic fluid was harvested for 48 h after virus inoculation, aliquoted, and stored at −80 °C.

Synthesis of nanocomposites
---------------------------

Oligonucleotides were synthesized by the phosphoramidite method on an ASM-800 DNA synthesizer (Biosset, Russia) using phosphoramidite monomers (Glen Research, USA). The polylysine (PL)-containing oligonucleotides (PL--DNA) were synthesized as described in \[[@R17]\]. The TiO~2~·PL--DNA nanocomposites were prepared by mixing PL--DNA and anatase nanoparticles (≈5 nm diameter) at room temperature for 20--30 min. The yield of the immobilization was ≈95%, with the capacity of the nanocomposites for oligonucleotides being ≈20 nmol/mg. A more detailed description of the nanocomposite preparation can be found elesewhere \[[@R17]\].

Antiviral activity of nanocomposites
------------------------------------

The MDCK cells in logarithmic phase were seeded at 100,000 cells/mL in RPMI-1640 nutrient medium containing 10% fetal calf serum (Gibco, USA) in 96-well plates (100 μL/well) and incubated at 37 °С, 5% CO~2~, and 100% humidity. The cells at ≈80% confluence were initially infected with one of the IAV subtypes, which was added into each well in RPMI-1640 medium (100 μL) containing trypsin (2 μg/mL) at a multiple infection of 0.1 TCID~50~/cell. The control sample was RPMI-1640 medium (100 μL) containing trypsin (2 μg/mL). After 1 h of virus adsorption at room temperature, the virus-containing medium was removed, and the cells were rinsed with RPMI-1640 medium without trypsin. The studied samples of the nanocomposite taken in RPMI-1640 medium without trypsin (100 μL/well) at a concentration of 5 μg/mL were applied to the infected MDCK cells, followed by incubation for 4 h at 37 °С, 5% CO~2~, and 100% humidity. After incubation for 4 h at room temperature, the medium containing the sample was removed, the cells were rinsed with RPMI-1640 medium without trypsin, and the same medium containing trypsin was added into each well (100 μL). After incubation for 48 h, serial 10-fold dilutions (from 10^−1^ to 10^−8^) of the culture virus-containing liquid from each well were applied to MDCK cells for 48 h to evaluate the virus titer. The presence of the virus was visually determined under a microscope by the cytopathic action and in the hemagglutination reaction with a 1% suspension of chicken erythrocytes. The virus titer was expressed in terms of TCID~50~/mL or log TCID~50~/mL ([Table 2](#T2){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}, respectively). The titer was evaluated by noting the highest dilution of the virus that caused the hemagglutination reaction.
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